Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B. Daly, Mary A. Dwyer, Allison W. Kurian et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B. Daly, Susan Darlow, Robert Pilarski et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 660
Genetic/Familial High-Risk Assessment: Breast and OvarianMary B. Daly, Jeffrey N. Weitzel, Jennifer E. Axilbund et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 650
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B. Daly, Susan Darlow, Robert Pilarski et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 507
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409